Pre-Course 1: Advanced Discussions in Vulvovaginal Diseases (requires separate registration)
Course Director: Colleen K. Stockdale, MD, MS
The Advanced Discussions in Vulvovaginal Diseases course is designed to provide an up-to-date review of vulvovaginal conditions and will discuss questions regarding a variety of common presenting conditions. Presentations will cover vaginitis with a focus on noninfectious and persistent, the "itchy" vulva, atrophy and vulvodynia, as well as vulvar procedures tips and tricks.
Course Level: Intermediate to Advanced
Speakers: Colleen K. Stockdale, MD, MS
Hope K. Haefner, MD
Kathryn C. Welch, MD
Cynthia A. Rasmussen, MD
Pre-Course 2: Screening for Anal Disease (requires separate registration)
Course Director: Lisa C. Flowers, MD
This course is for providers with experience in colposcopy of the female genital tract who may have background in high-resolution anoscopy through a previous course or are in practice. This course is designed to provide a current and comprehensive review including a discussion of cases (presentation, diagnosis, and management) regarding common presenting complaints.
Course Level: Advanced
Speakers: Lisa Flowers, MD, MPH
Naomi Jay, PhD, NP, RN
Michelle J. Khan, MD, MPH
Joel M. Palefsky, MD
Plenary: Racial Disparities
Moderator: Levi S. Downs, Jr., MD, MS
This timely and relevant session will present a comprehensive review of racial disparities in outcomes and screening for cervical cancer and head and neck cancers. We will address practical steps that providers and health systems can put in place to overcome these disparities by addressing implicit bias and systematic barriers to care.
Levi S. Downs, Jr., MD, MS
Racial Disparities in Cervical Screening & Cervical Cancer
Michelle J. Khan, MD, MPH
Racial Disparities in Head and Neck
Gypsyamber D’Souza, PhD, MPH
Plenary: Primary HPV Testing
Moderator: Philip E. Castle, PhD, MPH
This session will cover the implementation in the US - barriers, strategies that have been successful, and comparison to implementation in other countries with similar screening history; Self-collection for primary HPV screening; potential role, data re: sensitivity and specificity, patient interest/satisfaction, comparison to other screening strategies, other technologies in the pipeline that can achieve the same outcomes from a patient perspective, populations that could benefit; Impact on health disparities, reaction by organizations representing communities with POC, underserved communities; and HPV vs. co-testing: benefit and harms comparison.
Human Papillomavirus (HPV) Testing With and Without Cytology Co-Testing: Is the Juice Worth the Squeeze?
Philip E. Castle, PhD, MPH
Implementation in the U.S.—Barriers and Strategies
Walter K. Kinney, MD
The Challenges of the Diffusion of New Technologies to All Populations: The Case of HPV Testing
Electra D. Paskett, PhD
Self Collection for Primary HPV Screening
Mark S. Schiffman, MD, MPH
Plenary: New Frontiers for the HPV Vaccine
Moderator: Kimberly L. Levinson, MD, MPH
This plenary will briefly review the current HPV vaccine and available indications. Speakers will then discuss new uses for the current preventive vaccine as well as current treatment vaccine development for HPV related diseases. We will cover exciting vaccine prospects on the horizon for both oropharyngeal and lower genital tract diseases.
HPV Vaccine History, Indications, and Promising Uses for the Nonavalent HPV Vaccine
Kimberly L. Levinson, MD, MPH
Extending the Benefits of HPV Vaccination to the Prevention of Head and Neck Cancers
Anna R. Giuliano, PhD
Repurposing HPV Vaccinations for the Prevention of Head and Neck Cancer
Sara I. Pai, MD, PhD
Therapeutic Vaccines Under Development for Cervical Cancer
Leslie R. Boyd, MD
Plenary: HPV Ecology and Cervical Cancer Screening in Post-Menopausal Women
Moderator: Patti E. Gravitt, PhD, MS
Our understanding of the biology and natural history of HPV infection across the lifespan is evolving. This session is designed to update our understanding of the risks of HPV detection and cancer progression in postmenopausal women based on emerging evidence of transmission risk and viral latency/reactivation, and to consider the implications of this knowledge on screening and management among a large proportion of the screening population
New Acquisition and Viral Reactivation: HPV Natural History Through the Lifespan
Rachel L. Winer, PhD, MPH
Cervical Cancer and HPV by Age. Where Do We Stand on Risk at Older Ages?
Anne F. Rositch, PhD, MSPH
Overview of Screening Performance and Screening History Assessment in Postmenopausal Exiting Decisions,
Michelle I. Silver, PhD
Clinical Management and Counseling of Menopausal Women in HPV Screening Programs
Anne Hammer, MD, PhD
Significance and Differential Diagnosis of New HPV Detection
Maria DeMarco, PhD, MPH
Plenary: Beyond CDC Coaching: HPV Vaccination in Populations with Unique Barriers
Moderator: Deanna G.K. Teoh, MD, MS
In this session, participants will learn about unique barriers to HPV vaccination in certain populations, including the immigrant and other minority populations, LGBTQ+ population, and adolescent and young adult cancer survivors. This session will discuss strategies to overcome barriers to vaccination in populations for whom an “authoritative recommendation without detailed discussion” as recommended by the CDC may not be sufficient.
Preventing Secondary Malignancy: HPV Vaccination for Pediatric, Adolescent, & Young Adult Cancer Survivors
Deanna G.K. Teoh, MD, MS
Catch-up and Mid-Adult HPV Immunization: Focus on Low Income and Uninsured Adults
Sangini S. Sheth, MD, MPH
Plenary: Keynote and Top Oral Abstracts
Pap Smear to Papillomavirus: The Conquest of Cervical Cancer
Our progress towards prevention of cervical cancer as one of modern medicine’s great accomplishments. This presentation will highlight the evidence bringing us from the early days of Pap smears to the extraordinary contribution of human papillomavirus (HPV) testing and the increasing significance of HPV types.
Keynote Speaker: Robert D. Burk, MD
Top Oral Abstracts
To be Determined